Page last updated: 2024-12-09

sodium taurodeoxycholate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Taurodeoxycholic Acid: A bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. It is used as a cholagogue and choleretic, also industrially as a fat emulsifier. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

taurodeoxycholic acid : A bile acid taurine conjugate of deoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

taurodeoxycholate : An organosulfonate oxoanion that is the conjugate base of taurodeoxycholic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2733768
CHEMBL ID412272
CHEBI ID9410
SCHEMBL ID27304
MeSH IDM0021071

Synonyms (41)

Synonym
2-[(3alpha,12alpha-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid
CHEBI:9410 ,
SPECTRUM5_002017
taurodeoxycholic acid
taurodeoxycholate
sodium taurodeoxycholate
deoxycholyltaurine
tdca
2-[4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
tudcabil
hy209
taurodesoxycholic acid
hy-209
CHEMBL412272 ,
deoxy cholate
j339.140j ,
LMST05040013
n-(3alpha,12alpha-dihydroxy-5beta-cholan-24-oyl)-taurine
sodium taurodeoxylate
bdbm50375592
deoxytaurocholic acid
taurodeoxycholic acid sodium salt
BRD-K33572481-001-01-0
taurodeoxychloic acid
SCHEMBL27304
W-204225
taurodeoxycholic acid [who-dd]
taurine, n-(3.alpha.,12.alpha.-dihydroxy-5.beta.-cholan-24-oyl)-
2-(((3.alpha.,5.beta.,12.alpha.)-3,12-dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic acid
3.alpha.,12.alpha.-dihydroxy-5.beta.-cholanic acid-24-taurine
taurodesoxycholsaure
n-(3a,12a-dihydroxy-5b-cholan-24-oyl)-taurine
deoxytaurocholate
taurodesoxycholate
DTXSID00873418
6sb ,
Q7688896
deoxycholyltaurine; deoxytaurocholic acid; tdca;tudcabil
MS-29280
CS-0013959
HY-B1899

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No adverse effects or dose-related abnormalities were observed in the reproductive performance of either sex; no death or evidence of teratogenicity in fetuses were also observed."( Reproductive toxicity of taurohyodeoxycholic acid.
Feletti, F; Germogli, R; Tripodi, AS, 1993
)
0.29
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
" Based on the analysis using principle components analysis (PCA), toxic groups could be distinguished from their control groups, which suggested that the variance of the contents of bile acids could evaluate hepatotoxicity caused by ET and DB."( [Evaluation on hepatotoxicity caused by Dioscorea bulbifera based on analysis of bile acids].
Chen, CC; Hu, ZB; Ji, LL; Wang, JM; Wang, ZT; Xu, Y; Yang, L, 2011
)
0.37

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"5 microM, the rate of absorption decreases over a 20 min period, which also indicates some form of specific interaction between 2-acetylaminofluorene and the intestinal mucosa."( Absorption of 2-acetylaminofluorene in the guinea-pig colon.
Dougherty, MA; Nahrwold, DL; Rose, RC; Weimer, GR, 1979
)
0.26
" After oral administration the extent of bioavailability compared with intra-muscular administration is low, due to a first pass effect."( Buccal delivery of thiocolchicoside: in vitro and in vivo permeation studies.
Artusi, M; Colombo, P; Junginger, HE; Santi, P, 2003
)
0.32
"1-fold increase in the bioavailability (i."( Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
Chung, SJ; Shim, CK; Song, KH, 2005
)
0.33
"1-fold increase in the bioavailability of sCT could be achieved from the TDC proliposomes."( Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts.
Chung, SJ; Shim, CK; Song, KH, 2005
)
0.33
" A dose-dependent relationship of L-penetratin and insulin bioavailability was statically significant."( Effect of cell-penetrating peptides on the nasal absorption of insulin.
Imai, J; Isowa, K; Khafagy, el-S; Morishita, M; Takayama, K, 2009
)
0.35
"In the current study the involvement of ion pair formation between bile salts and trospium chloride (TC), a positively charged Biopharmaceutical Classification System (BCS) class III substance, showing a decrease in bioavailability upon coadministration with food (negative food effect) was investigated."( Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride.
Amidon, GL; Heinen, CA; Langguth, P; Reuss, S, 2013
)
0.39
" Pre-minisphere emulsions of PEs combined with sCT increased absolute bioavailability (F) compared to native sCT following rat intra-jejunal (i."( In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPillĀ®) of salmon calcitonin.
Aguirre, TA; Brayden, DJ; Coulter, IS; Rosa, M, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Only bile, but not secretin intravenously, both applied in a dosage equivalent with respect to their hydrokinetic action, caused a significant increase of enzyme output and enzyme concentration as well."( Na-taurodeoxycholate acts as a specific intestinal stimulus of exocrine pancreatic secretion in man.
Danzl, C; Fiedler, F; Hempen, I; Hotz, E; Lehnert, P; Mitra, H; Riepl, R, 1987
)
0.27
"0 gm given over 12 hours in a variety of dosing schedules."( Intranasal administration of deferoxamine to iron overloaded patients.
Ambruso, DR; Githens, JH; Gordon, GS; Robinson, WA, 1989
)
0.28
" For the increase of integrated plasma VIP concentrations after TDC no dose-response relation could be established."( Effect of intraduodenal bile and taurodeoxycholate on exocrine pancreatic secretion and on plasma levels of vasoactive intestinal polypeptide and somatostatin in man.
Fiedler, F; Lehnert, P; Riepl, RL; Teufel, J, 1994
)
0.29
" The livers and intestines were separately perfused and dose-response curves (0."( Hepatic uptake and intestinal absorption of bile acids in the rabbit.
Aldini, R; Cerre, C; Galletti, G; Lenzi, PL; Montagnani, M; Polimeni, C; Roda, A; Roda, E, 1994
)
0.29
" Dosage range 12-15 mg/kg daily for both groups which were comparable at to age, sex, duration and stage of the disease, as well as for all liver laboratory tests."( [Taurodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid].
Bernocchi, P; Fedeli, S; Ferri, F, 1993
)
0.29
" A concurrent drop in Rt was noted at all TDCA concentrations, the duration of which correlated with dosage and degree of histological damage."( Acute effects of bile acids on the pancreatic duct epithelium in vitro.
Alvarez, C; Bass, BL; Fasano, A, 1998
)
0.3
" Thus, in this work, a dose-response study was carried out to investigate the in vitro cytotoxic effect of major unconjugated and tauro- (T) or glyco- (G) conjugated bile acids and to compare this as regards their ability to inhibit DNA synthesis."( Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture.
Marin, JJ; Martinez-Diez, MC; Monte, MJ; Serrano, MA, 2000
)
0.31
" Two dosage forms, a bioadhesive disc and a fast dissolving disc for buccal and sublingual administration of thiocolchicoside, respectively, were designed."( Buccal delivery of thiocolchicoside: in vitro and in vivo permeation studies.
Artusi, M; Colombo, P; Junginger, HE; Santi, P, 2003
)
0.32
" In conclusion, the SmPillĀ® technology is a potential dosage form for several peptides when formulated with PEs and coated for regional delivery."( Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre, TAS; Aversa, V; Brayden, DJ; Coulter, I; Guterres, SS; Pohlmann, AR; Rosa, M, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bile acid taurine conjugateA bile acid conjugate resulting from the formal condensation of a bile acid with the amino group of taurine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Bile Acid Biosynthesis1761
Congenital Bile Acid Synthesis Defect Type II1761
Congenital Bile Acid Synthesis Defect Type III1761
Familial Hypercholanemia (FHCA)1761
Zellweger Syndrome1761
Cerebrotendinous Xanthomatosis (CTX)1761
27-Hydroxylase Deficiency1761

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)60.00000.20005.677410.0000AID681389
Ileal sodium/bile acid cotransporterHomo sapiens (human)Ki17.20003.30006.400010.0000AID681332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)3.45670.02372.52598.9000AID1261245; AID1261246; AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 1A5Rattus norvegicus (Norway rat)Km5.80004.30006.39608.8000AID681360
Sodium/bile acid cotransporterRattus norvegicus (Norway rat)Km7.40003.70005.36677.4000AID679118
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km3.50000.01503.49967.0000AID679332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
sodium ion transportIleal sodium/bile acid cotransporterHomo sapiens (human)
response to bacteriumIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid and bile salt transportIleal sodium/bile acid cotransporterHomo sapiens (human)
transmembrane transportIleal sodium/bile acid cotransporterHomo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingIleal sodium/bile acid cotransporterHomo sapiens (human)
bile acid:sodium symporter activityIleal sodium/bile acid cotransporterHomo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
microvillusIleal sodium/bile acid cotransporterHomo sapiens (human)
apical plasma membraneIleal sodium/bile acid cotransporterHomo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID681567TP_TRANSPORTER: RT-PCR in vivo, liver of CD-1 mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
AID680629TP_TRANSPORTER: inhibition of BSP uptake (BSP: 2 uM, TDCA: 100 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID1261227Agonist activity at human TGR5 S21A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261236Agonist activity at human TGR5 Y240F mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261226Agonist activity at human TGR5 E169A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 0.1 to 2.5 uM incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID681571TP_TRANSPORTER: RT-PCR in vivo, liver of CD-1 mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID681360TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID681332TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells1998The American journal of physiology, 01, Volume: 274, Issue:1
Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID1261230Agonist activity at human TGR5 E169A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter assay relative to wild type2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261233Agonist activity at human TGR5 R79A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID679118TP_TRANSPORTER: uptake in NTCP-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID1261232Agonist activity at human TGR5 L244A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261242Agonist activity at human TGR5 S270A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID682142TP_TRANSPORTER: RT-PCR in vivo, liver of CD-1 mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
AID1261241Agonist activity at human TGR5 N93A mutant expressed in HEK293 cells assessed as reduction in forskolin-induced intracellular cAMP level at 0.1 to 10 uM incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID681658TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 5 uM, TDCA: 50 uM) in membrane vesicles isolated from Bsep-expressing Balb-3T3 cells2000Gene, Jan-04, Volume: 241, Issue:1
Molecular cloning and characterization of the murine bile salt export pump.
AID1261234Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID681136TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells1999Molecular pharmacology, Apr, Volume: 55, Issue:4
Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney.
AID1261246Agonist activity at wild type human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID422552Binding affinity to human pancreatic recombinant 1B PLA2 expressed in Escherichia coli at 100 uM by saturation transfer difference NMR spectroscopy2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID681349TP_TRANSPORTER: uptake in ASBT-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID680252TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 20 uM, TDCA: 200 uM) in Xenopus laevis oocytes1994Hepatology (Baltimore, Md.), Aug, Volume: 20, Issue:2
Functional characterization of the basolateral rat liver organic anion transporting polypeptide.
AID1261244Agonist activity at human TGR5 Y240F mutant expressed in HEK293 cells assessed as reduction in forskolin-induced intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261243Agonist activity at human TGR5 R79A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID422544Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID680579TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, TDCA: 500 uM) by Taurodeoxycholate at a concentration of 500uM in membrane vesicle from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID681361TP_TRANSPORTER: uptake in Oatp3-expressing COS cells2000American journal of physiology. Gastrointestinal and liver physiology, Dec, Volume: 279, Issue:6
Expression, transport properties, and chromosomal location of organic anion transporter subtype 3.
AID1261235Agonist activity at human TGR5 N93A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID679153TP_TRANSPORTER: RT-PCR in vivo, liver of CD-1 mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
AID1261238Agonist activity at human TGR5 L244A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID681568TP_TRANSPORTER: RT-PCR in vivo, liver of CD-1 mouse2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID680578TP_TRANSPORTER: inhibition of Etoposide glucuronide uptake (Etoposide glucuronide: 0.094 uM, TDCA: 500.0 uM) in membrane vesicles from MRP3-expressing Sf9 cells2003The Biochemical journal, Jan-01, Volume: 369, Issue:Pt 1
Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter.
AID1261237Agonist activity at human TGR5 S270A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261240Agonist activity at human TGR5 Y240A mutant expressed in HEK293 cells assessed as reduction in forskolin-induced intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261231Agonist activity at human TGR5 Y240A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level at 10 uM incubated for 16 hrs by luciferase reporter gene assay relative to wildtype2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261239Agonist activity at human TGR5 L244A mutant expressed in HEK293 cells assessed as reduction in forskolin-induced intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID1261245Agonist activity at human TGR5 Y89A mutant expressed in HEK293 cells assessed as rise in intracellular cAMP level incubated for 16 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Nov-02, Volume: 104Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.
AID422543Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID422555Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID679568TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurochorate: 10 uM, TDCA: 100 uM) in Xenopus laevis oocytes1994The Journal of clinical investigation, Mar, Volume: 93, Issue:3
Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter.
AID679332TP_TRANSPORTER: uptake in Oatp1-expressing HeLa cells2003American journal of physiology. Gastrointestinal and liver physiology, Nov, Volume: 285, Issue:5
Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake.
AID422554Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control2009Journal of natural products, Jan, Volume: 72, Issue:1
Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID678843TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells2000Gastroenterology, Feb, Volume: 118, Issue:2
Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID681389TP_TRANSPORTER: inhibition of E217betaG uptake in membrane vesicles from MRP4-expressing HEK-293 cells2003The Biochemical journal, Apr-15, Volume: 371, Issue:Pt 2
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (436)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990134 (30.73)18.7374
1990's105 (24.08)18.2507
2000's121 (27.75)29.6817
2010's60 (13.76)24.3611
2020's16 (3.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.46 (24.57)
Research Supply Index6.11 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index45.51 (26.88)
Search Engine Supply Index2.26 (0.95)

This Compound (30.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.67%)5.53%
Reviews2 (0.45%)6.00%
Case Studies1 (0.22%)4.05%
Observational0 (0.00%)0.25%
Other442 (98.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]